Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Securities_and_Exchange_Commission
|
| gptkbp:acquisition |
gptkb:Bausch_&_Lomb
gptkb:Actavis Actavis Group |
| gptkbp:capacity |
1 million shares (average)
|
| gptkbp:ceo |
gptkb:Paul_Bisaro
gptkb:Robert_Stewart |
| gptkbp:dividend_yield |
0.5% (2013)
|
| gptkbp:employees |
approximately 10,000
|
| gptkbp:founded |
gptkb:1983
|
| gptkbp:headquarters |
gptkb:Parsippany-Troy_Hills,_New_Jersey
gptkb:New_Jersey |
| https://www.w3.org/2000/01/rdf-schema#label |
WPI
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:ipo |
gptkb:2001
|
| gptkbp:market_cap |
$4.5 billion (2014)
|
| gptkbp:material |
common stock
|
| gptkbp:partnership |
gptkb:pharmaceuticals
|
| gptkbp:production_company |
Watson Pharmaceuticals
|
| gptkbp:products |
generic drugs
branded drugs |
| gptkbp:revenue |
$3.5 billion (2012)
|
| gptkbp:stock_exchange |
gptkb:New_York_Stock_Exchange
|
| gptkbp:stock_symbol |
gptkb:WPI
|
| gptkbp:subsidiary |
gptkb:Actavis,_Inc.
|
| gptkbp:traded_on |
gptkb:NYSE
|
| gptkbp:website |
www.watson.com
|